| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SLNO Stock Overview
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Soleno Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$0.97 |
| 52 Week Low | US$0.13 |
| Beta | 0.24 |
| 1 Month Change | 4.28% |
| 3 Month Change | 1.16% |
| 1 Year Change | -77.09% |
| 3 Year Change | -89.92% |
| 5 Year Change | -89.31% |
| Change since IPO | -99.04% |
Recent News & Updates
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment
Soleno Therapeutics (NASDAQ:SLNO) is trading 49% higher premarket after the U.S. Food and Drug Administration said that data from a withdrawal phase study would be sufficient to address concerns regarding the overall efficacy data supportive of a New Drug Application (NDA) submission for its drug DCCR (diazoxide choline) to treat Prader-Willi syndrome. The stock is set to touch its highest in 4 months. Soleno had submitted a proposal to add a withdrawal period to Study C602 in order to obtain additional controlled data requested by the FDA to support an NDA, the company said. The Company continues to work collaboratively with the FDA to finalize specific details of the study design and plans to initiate the randomized withdrawal period in the current quarter, with top-line data expected in the first quarter of 2023. Prader-Willi syndrome is genetic disorder that causes obesity, intellectual disability and shortness in height.
Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
| SLNO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.1% | 1.4% | 3.6% |
| 1Y | -77.1% | -19.6% | -9.6% |
Return vs Industry: SLNO underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: SLNO underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| SLNO volatility | |
|---|---|
| SLNO Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SLNO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SLNO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 20 | Anish Bhatnagar | https://soleno.life |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. Fundamentals Summary
| SLNO fundamental statistics | |
|---|---|
| Market Cap | US$23.39m |
| Earnings (TTM) | -US$23.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs SLNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLNO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$23.42m |
| Earnings | -US$23.42m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLNO perform over the long term?
See historical performance and comparison